FlandersBio on Twitter

Follow us on Twitter

Archive for March 2016 - News

Archive for March 2016 - Nieuws

in het nederlands in english

FlandersBio informs you about important regional and national life sciences news. Send us your news. If your news is of interest to the life sciences community, we will post it on our website.

FlandersBio informeert u over belangrijk nieuws op het vlak van de biowetenschappen. Bezorg ons jouw nieuwtjes. Als het interessant is voor de sector, zullen wij het op onze website plaatsen.



A mysterious inflammatory disease has been afflicting a Flemish family for three generations, causing severe skin lesions, fevers, pain and exhaustion. This disease, which previously had no known cause or cure, has now been identified as Pyrin Associated Autoinflammation with Neutrophilic Dermatosis (PAAND), and has also been found in families in England and France. New research by Adrian Liston (VIB/University of Leuven, Belgium), Seth Masters (Walter and Elisa Hall Institute, Australia), Carine Wouters (University of Leuven, Belgium) has found the genetic mutation causing the disease and also identified an effective treatment. This research was published in the international scientific journal Science Translational Medicine. read more

Celyad successfully completes safety follow-up of the first patient in the third dose level of its NKR-2 Trial


Celyad (Euronext Brussels and Paris, and NASDAQ: CYAD), a leader in the discovery and development of engineered cell therapies, with clinical programs in cardiovascular diseases and immuno-oncology, today announced the completion of the 21-day safety follow-up of the first patient enrolled in the third dose level in the Phase I/IIa clinical trial, evaluating the safety and feasibility of its NKR-2 T-cell therapy using T-cells with NKG2D receptor in cancer patients suffering from Acute Myeloid Leukemia (AML) or Multiple Myeloma (MM). No safety issue was reported. read more

ADx NeuroSciences announces capital increase


ADx NeuroSciences, the Ghent-based developer of diagnostics and biomarkers for neurodegenerative diseases, has announced the conclusion of its third financing round. The capital increase is financed by two new individual private investors together with the existing shareholders. read more

Belgian Alzheimer specialist ADx NeuroSciences joins forces with Quanterix developing a unique blood test for concussion


ADx NeuroSciences signs an exclusive deal with Quanterix Corporation, a U.S.-based leader in high definition diagnostics, focused on the development and commercialization of a unique blood test identifying traumatic brain injury (TBI). The companies collaborated on the development of a test for the detection of Tau, a protein in the brain associated with Alzheimer’s disease. The two companies now confirmed their commitment to a long-term collaboration. The innovative blood test successfully developed and launched by Quanterix including ADx biomaterials and know-how, promises to introduce a revolution in the diagnosis and monitoring of traumatic brain injuries. read more

TiGenix: Transparency Information


TiGenix NV (Euronext Brussels: TIG) publishes information in accordance with articles 15 and 18 of the Belgian Law of May 2, 2007 regarding the publication of major holdings in issuers whose securities are admitted to trading on a regulated market and including various provisions (the Law) and the Royal Decree of February 14, 2008 regarding the publication of major holdings. read more

Publication of the annual report and invitation to the Annual and Extraordinary Shareholders' Meetings


Today Galapagos NV (Euronext & NASDAQ: GLPG) has published its Annual Report for the financial year 2015. read more

Bone Therapeutics Reports Full Year 2015 Results


BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the bone cell therapy company addressing high unmet medical needs in the field of bone fracture repair, fracture prevention and spinal fusion, today reports its full year results for the year ending 31 December 2015, prepared in accordance with IFRS as adopted by the European Union. read more

Kiadis Pharma to host a webcast of the full dataset on the primary endpoint of its single-dose Phase II trial with ATIR101™


Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company developing innovative T-cell immunotherapy treatments for blood cancers and inherited blood disorders, today announces it will host a webcast on Monday April 4, 2016 at 18:00 CET to discuss the full dataset on the primary endpoint (Transplant Related Mortality at 6 months post transplantation) of its single-dose Phase II trial (NCT01794299/EudraCT 2012-004461-41) with its lead product ATIR101™. During the webcast, the data will also be put into perspective with other current approaches in the literature for patients lacking a fully matched donor, such as the Baltimore approach using post-transplant cyclophosphamide. read more

MDxHealth Partners with Andros Men's Clinic to Offer SelectMDx for Prostate Cancer


MDxHealth SA (Euronext: MDXH.BR), announced today that it has partnered with Andros Men's Health Clinic (Andros Mannenkliniek) in The Netherlands to offer the SelectMDx(TM) for Prostate Cancer test to their patients. read more

Bone Therapeutics reports initial efficacy results from its PREOB® Phase IIA trial in severe osteoporosis


BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the bone cell therapy company addressing high unmet medical needs in the field of bone fracture repair, fracture prevention and spinal fusion, today announces the 12-month efficacy results from the first cohort of seven1 patients treated with PREOB® in its Phase IIA severe osteoporosis trial. These initial data demonstrate positive effects on pain and osteoporosis blood markers of a single administration of PREOB®. read more

Join E-news

Interested in a regular update of the life sciences and biotech sector in Flanders? Subscribe to our newsletter.

Subscribe now

Back to top